McBride plc

Right, welcome to everybody. We're just going to wait half a minute or so to let everybody get on to the event today. There's been a lot of interest, which is good to see, so just bear with us. Right, okay, I think we've got a decent number now. So welcome to the webinar today from McBride, who'll be covering their recently announced interim results and also talking a little bit about the outlook for the business. I want to say administrative points first. This presentation is being recorded, so should you miss any of it, you can watch it again. We will be very keen to address questions after the formal presentation, which you can submit via the question button on your screen. And the presentation deck that the boys will be talking to is already available on the McBride Investor Relations page as well, along with lots of other useful materials. We're very pleased to be welcoming back CFO Mark Strickland, and the CEO Chris Smith and I'm now going to pass over to you Chris if you can start the presentation.

Thanks Andy, good morning to everyone and welcome to our interim results deck and presentation for the six months to the 31st of December 2025. We'll cover today on the next slide, please, Andy, a series of, I will cover off headlines and an update on our business progress before I hand over to Mark, who will take you through a more detailed look at some of the financials. And then I'll come back to myself for the outlook and then into questions, as Andy said. Before I step through the various slides, I'd just like to comment that there are three key themes that the past six months can really be summarised by. First, continued delivery of our strong financial and operational performance for the third consecutive year now. Secondly, the passing of a significant milestone in our transformation journey with our first SAP Go Live in November. And then third, clear demonstration of a balanced approach to capital allocation to support both short-term shareholder returns and longer-term value creation from business investment. Next slide, please, Andy. This is the sixth set of results, interims and finals that I presented where the group has reported profitability levels at double the historic average, cementing our new financial strength and our optionality to deploy resources to support future growth in line with our ambitions as we set out at our Capital Markets Day about two years ago. The market continues to move in favour of the private label offer we provide, with the latest data showing that private label share has started rising above recent all-time highs, providing a solid platform for McBride to continue to prosper. Our divisional and central teams continue to drive the business forward, tightly aligned to their strategies, supporting our customers as our private label proposition expands to provide value to the retailers and consumers alike. McBride's private label volumes continue to grow this past period, albeit at slightly lower levels than we saw in the past two years, with total sales revenue increasing just under 1% to £475 million. We have secured a robust pipeline of new business wins, expected to start in the second half year, leading to positive momentum as we exit financial year 2026 and we move into the next financial year of 2027. Our excellence and transformation agenda has continued at pace these past six months. Productivity and other operational improvements, together with tight management of overheads, has seen margins maintained despite competitive pricing pressures and inflationary pressures. EBITDA, EBITDA and PBT all remain consistent with the first half of last year, with EBITDA margins just under 9% for the first half and with the full year expected to be over 9%. I am really pleased to be able to confirm that our first SAP S4 HANA Go Live in the UK was successfully completed in the period after two years of preparation and design. This multi-year programme is the platform for future efficiency and operating excellence as we upgrade McBride to the latest best-in-class ERP systems. Our continued strong profit levels and cash generation has supported a balanced approach to capital allocation. In the period, nearly £13 million of shareholder returns were deployed in the form of reinstated dividends, share buyback programme and share purchases to reduce future dilution from employee share awards. Our overall share price rise since September 2025 represents a market cap rise of approximately 40%. Additionally, capital expenditure rose to support growth, efficiency and transformation programmes. The group remains active in considering all options for deployment of capital in seeking to grow shareholder value. I'm now going to move on to provide an update on a series of key business progress topics. At us Capital Markets Day in February 2024, the next slide please Andy, We set out a number of key ambitions to measure our progress. At this midpoint of FY26, we remain committed to these key targets over the coming years, and our progress since 2024 continues to perform in line. Our volume growth, whilst a little slower these past six months, is comfortably ahead of the targets set in 2024, cumulatively. We have an encouraging set of contract wins starting in the second half, which is expected to support better growth rates into FY27 and a number of other material growth options in development at this time. Our EBITDA margins are consistently around the 9% level with another 1% required to reach our 10% ambition and almost at the double of the level of the historic levels of 5%. We said at the capital markets days in February 2024 that shareholders should expect some minor variability of this ratio as modest input cost swings will either benefit or impact the group's profitability between periods. Our debt position remains well within our targets and this is after nearly £13 million deployed in the past six months for shareholder returns. Our long-term committed facilities and liquidity availability provides ample scope for further capital deployment in pursuit of our strategic ambition. Rocky remains well above the targets and our work on excellence and transformation is delivering tangible improvements to support and develop the robust platform the group needs to support long-term success. Moving on to an update on the markets that we supply. We present here the usual panel data which we receive each quarter. As a reminder, the data is 12 months trailing value and volumes. It covers the top five economies of Europe, all the bricks and mortar retailers and all the household categories that we supply. We've been tracking this data for over four years now. Having grown substantially between 2022 and 2024, private label market share in volume terms, as shown by the green line on that chart, stabilised over the last 12 to 18 months. This latest data insight, however, shows that the overall total market continues to grow a little bit towards the lower end of our 1.1 to 2 times, sorry, 1 to 2% projections. with private label again outperforming brands across all categories, with private label volume share now up to 36.1%, a 0.3% rise compared to the last four quarters. We will wait to see over the next two data drops if this further rise is sustained, but this latest data confirms our view that the more likely direction of travel is for private label to continue to take share and not revert back to pre-2022 levels. Moving on to the divisions, and I'll now give a brief update from all the businesses. Next slide, please, Andy. Mark will cover off the financial performance later, but we have seen strong profits progress overall in unit dosing and aerosols, but liquids and powders were slightly weaker. The liquids division has had a very busy period, and at the same time has had to handle the first go-live of the S4 HANA programme at the UK liquids site. The division saw overall volumes higher, especially from contract manufacturing, which was up 9%, with private label flat. The uncertainty on the rollout of the EU's Deforestation Regulation, or EUDR, has seen pressure on certain raw materials, especially for the liquids business, where palm oil derivatives are actively used. As a result, the division did see modest rises in material costs in a market where such small rises are not really able to be passed on. The business, however, was vigilant, of course, in its cost management and its product engineering, and it's managed its margins very well in the period. With future growth anticipated, especially from laundry, the division continued to invest in capacity and new packaging formats to be able to secure new business going forward. In unit dosing, we saw a strong operational performance, with the benefits of our Flexilence programme, where we now ensure that all our pod formats can be supplied in all the various packaging formats required by customers, yielding output and headcount efficiencies. Overall volumes here were lower year over year, but all in contract manufacturing, where a lost contract from last year annualised out at December. Private label volumes were flat, some ins and some outs amongst various customers, and some delays in a few product launches. But strong wins in recent tenders are expected to launch in the second half and early into FY27 to provide good growth prospects ahead. The powders business continues to outperform its strategic targets overall. The market for private label laundry has remained steady, with private label share growing as branded volumes continue to fall. Total volumes for our division in McBride in powders were broadly flat, with an overall private label slightly weaker than our contract business, which is about 40% of revenues in this division. Like the other divisions, recent wins, expected to launch again in the next six months or so, will provide good growth in future periods. In the meantime, strong operational control and focus has seen margins steady, with some automation capital investment introduced, helping drive margins higher. Our aerosols team have delivered again this year. Volumes were 15% higher and are now close to the 100 million cans target. Very strong growth in Germany was a result of focus over the past few years in this targeted market. A £2.5 million investment in a new production line is mostly complete now and is providing the capacity needed to take us past the 100 million cans level target. And finally, our Asia business had a bit of a mixture with weaker than expected private label sales in Southeast Asia and a quieter Australia with a loss of one part of a traded goods supply from our European business. However, prospects are looking more positive with our first household wins in Australia for products made in Malaysia expected to launch in the next months or so and a series of new contract manufacturing opportunities in discussion. Moving on to an update on our transformation programme or excellence agenda, as I call it, and this has continued at pace through the period. After over two years of setup and design work from the SAP team, we successfully launched the new global template with the first go live at the start of November in the UK Business and Corporate Centre. It is pleasing to confirm that the business is operating as usual, with some limited disruption in the early few weeks to our warehouse operations, where, whilst the systems were working, we became capacity limited. We did miss some sales in that short period of time, which we estimate to be about £3 million, with a roughly £1 million impact to EBITDA. This challenge was resolved quickly, and the business has seen record output and shipment days since. The focus here has now moved quickly to lessons learned, and we're now deep into planning the wave two rollout of this new global template to ensure we maintain pace towards the efficiencies and benefits that will accrue once we have more locations on this new platform. The other three main programmes in the overall plan, service, commercial and productivity, are all now into business as usual, with the service programme completing in September and the commercial excellence project completing in December. both are yielding good results with improved processes in use across the business and visible kpi improvements next slide please the past six months has demonstrated the group's flexible approach to capital allocation with the strength of the group's trading position and its funding capacity we have deployed nearly 13 million pounds in shareholder returns At the AGM in December, shareholders approved the board's recommended recommencement of annual dividends, with a resulting payment in November of £5.2 million. In light of a market valuation so far below the board's view on where the group should be valued, the board launched two value initiatives in the autumn. First, £6.4 million was spent on buying shares at an average price of £1.26 through the Employee Benefit Trust, or EBT, in order to fund the EBT with adequate share levels to use for satisfying future incentive awards that are expected to vest in the next two years. These share awards would normally be satisfied by new issue shares, thus diluting the total shares in issue And hence this action worth approximately 0.7 pence per share of reduced dilution in future EPS calculations. Secondly, the board launched a £20 million share buyback scheme in December. There was only one month of buying until the end of the half year, but £1.3 million had been deployed to 31st of December. All of these actions have supported a strong recovery in the share price and our market capitalisation, up approximately 40% since final results in September last year. A significant rise, but as a reminder, we are still only trading on a 4.9 times EV EBITDA multiple. At this point, I'm now going to hand over to Mark for a more detailed financial review.

Thank you, Chris, and good morning, everyone. the McBride business has delivered another solid set of results. As well as delivering good results, the business has also demonstrated a balanced approach to capital allocation, prioritising short-term shareholder returns whilst at the same time retaining the flexibility to fund our longer-term ambitions. As a result, I continue to have huge optimism for what the business can continue to deliver for its shareholders into the future. So looking at the financial highlights. Group revenues were up £3.8 million, 0.8% on an actual basis, but on a constant currency basis they were down slightly, 2.1%. Whilst private label and contract manufacturing volumes were both up, McBride branded volumes suffered slightly and declined. Adjusted operating profit was down slightly to £31.5 million. Without the SAP impact, adjusted operating profit would most likely have been up slightly. As in previous years, profit levels had been maintained through good margin management and overheads cost control. Adjusted EBITDA at £41.8 million was on a par with the previous year's first half. Earnings per share were down to 10.8 pence per share, predominantly due to a particularly hard prior year comparator in relation to taxation, which was 25% the last year, first half, versus 30% this year. We expect full year 2026 taxation to be broadly in line with the full year prior year rates. Over the last three years, we have progressively strengthened our balance sheet through cash generation and debt control. this period being no different. For the first half of the financial year, our free cash flow was a generation of £24 million, and our net debt only increased slightly to £120.6 million, despite the nearly £13 million paid out in dividend, the EBT and on-share buyback. This shows that the business, through its proactive capital allocation policy, has the ability to balance both the short-term shareholder returns, whilst retaining a flexible platform for future investments in growth, be they organic or through M&A type activities. Looking at financial performance. This slide looks at the group and divisional performance on both an actual and constant currency basis. There were three main drivers of the actual revenue growth of 0.8%. One, firstly volume, secondly price and mix, and thirdly FX. The volume growth of 0.4% arose from contract and private label volume growth, combined with the aerosol's continued growth. And as I said earlier, that was offset by a reduction in the McBride branded volumes. The second impact was the price and mix impact with two elements at play. Firstly, there's been an element of pricing pressure, but this has predominantly been offset through product re-engineering and ongoing margin management. Let me explain that further. In other words, whilst the selling price may be lower, the profitability is often similar to other products, as these are often lower cost format products. Secondly, there were more sales of lower value products in the first half of the financial year compared to that of the prior financial year. The third and final impact was FX, mainly with the pound-euro exchange rate moving towards the 1.15 euros to the pound. Next, the divisional review, so looking at liquids. At a revenue of £269 million, the liquids division represents around 57% of the group. As mentioned earlier by Chris, there was a limited impact in November and December from the SAP S4 HANA Go Live. Despite this, volumes grew 0.1%, with most markets stable and only France displaying a slight decline. Margins were impacted by competitive pressures, inflation and some marginal raw material increases that couldn't be passed on to the customers given their small size. The division still delivered an adjusted operating profit of £17.7 million, which represents a return on sales of 6.6%. We continue to invest in this business for the future. Now moving on to unit dosing. For the first half of the financial year, the unit dosing division delivered a revenue of £116 million. On a revenue basis, the unit dosing represents circa 24% of the group. Whilst contract manufacturing volumes were weaker in the first half, the outlook is good for year-on-year overall volume growth in the second half of the financial year. The division delivered improved profitability in the period of £12.5 million as a result of continued production efficiencies, the benefits of transformation and ongoing tight overhead cost control. At 10.8%, the division's return on sales is a pleasing step up from the prior year. Finally, the unit dosing division, through its flexible initiative and the range of its formats it can now offer, for example, its soft pods portfolio, continues to be well set to continue to gain business in future tenders. Moving on to powders. At circa 9.5% of our overall revenue, the powders division operates within an overall steadily declining market. Sales at £44.9 million were lower than expected, impacted by slightly softer private label demand, primarily in the UK, together with delayed launches of new contracts and product mix changes. Adjusted operating profit declined by £1.1 million to £3 million, mainly due to the aforementioned lower revenue. However, because of good cost control, operational efficiency, and again, product cost engineering, the division continues to deliver a healthy return on sales in line with our medium term expectations. Finally, as with unit dosing, this business segment has a good pipeline for growth into the future. Now moving on to aerosols and Asia Pacific. Between them, Aerosols and Asia Pacific represents circa 9.5% of the group's revenue. Over the last few years, our aerosols division has been a huge success story. This was no different for the first half of 2026. Volumes grew by some 14.6%, whilst revenue grew by 18.1%, to £33.9 million. delivering an adjusted operating profit of £2.1 million and closing in on our mid-term return on sales ambitions. The growth is supported by significant contract wins in Germany, combined with personal care launches elsewhere in Europe. The first half of financial year 2026 also saw the continuation of the significant investments for capacity expansion at the Rosborden site in France. This investment is on course for completion in the second half of this financial year. Our smallest division, Asia Pacific, has been impacted by subdued private label demand in Southeast Asia and has had to focus on cost management to preserve its profitability. That said, it has made good progress in private label household in Australia. Whilst currently being an incubator business, we still remain optimistic that there are significant opportunities which will mean that we will be able to grow this business over the next couple of years. Now looking at costs. For the first half of the 2026 financial year, input costs remain flat and benign overall, but as you can see from the left-hand chart, they still remain significantly higher than in 2021. Inflation is still prevalent and some costs are still rising, albeit at slower rates than over the last few years. Hence, McBride's continuing focus on margin management has been key to the delivery of this solid set of results. This consistency of performance means that McBride, as a group, remains very well placed to sustain underlying profits in future years. As with most businesses, technology remains a key focus, and indeed McBride has embraced new technology, believing that this will be a key positive differentiator going forward. Chris has indicated that the Wave 1 of the S4 HANA project has successfully gone live in the UK, and we expect to complete the rollout of the project during the 2028 financial year, which is in line with what we indicated when we set sail on the project. We continue to invest into and benefit from our data analytics function. Real life example of this capability is some of the market analysis information that you saw in Chris's earlier presentation. In terms of overheads, as you would expect, we continued our focus on cost optimisation. Overhead costs have been tightly controlled with reductions in both distribution and administrative costs as a percentage of revenue. Moving on to other financials. Year-on-year interest remained broadly flat, as did interest cover. Exceptional costs were £2.4 million relating to the SAP S4 HANA implementation and an ongoing review of the group's strategic growth options. Regarding taxation, the effective tax rate in the first half was 30%, which compares to the first half in 2025 of 25%, but a full year rate of 32% in 2025. The actual tax paid in half one was £1.8 million, compared to £7.1 million the previous year. as the cash payments normalised to the payment of in-year liabilities only, as opposed to FY25 when there was an element of catch-up from the financial year 2024. At £14.8 million, capital expenditure levels were up from £12 million the previous year, as the business continued to invest in the future. It is expected that the group will spend around £30 to £33 million over the current current full year and that the level of expenditure will continue at circa £30 million for the following year before dropping off in line with the completion of the SAP project. Finally, on to net debt. As indicated at the start of my presentation, the business continues to generate strong cash flows and resulting in net debt control and the small increase to 1.20, 1.20.6 million. The business has strong core liquidity with around 135 million of headroom and also has an unutilized 75 million euro accordion facility, providing continued optionality for future capital allocation decisions. In conclusion, the business continues to be run well. The shareback delivers good value for our shareholders. As a result of the successful SAP Global Template implementation, future implementation risk has been significantly reduced, and the business still has optionality through its balance sheet strength. Thank you, and I'll now pass you back to Chris.